MarketCap
Facebook
X
TelegramQuarterly report 2025-Q3
added 11-05-2025
Zimmer Biomet Holdings Cost of Revenue 2011-2026 | ZBH
Cost of Revenue is a financial metric that reflects all direct costs associated with the production of goods or the provision of services that directly led to revenue during the reporting period. It is the total amount of expenses incurred by the company to deliver its products or services, including both production costs and related expenses necessary for delivery or customer support.What is included in the cost of revenue
| Cost Category | Examples |
|---|---|
| Production Costs | Materials, wages of production staff, depreciation of equipment |
| Service and Support | Customer service, user support, technical assistance |
| Delivery and Logistics | Packaging, delivery of goods to customers |
| Hosting and Infrastructure | Servers, cloud platforms (especially for IT and SaaS companies) |
| Content and Licenses | License purchases, production royalties (e.g., in streaming services) |
Importance of the Metric
- Helps to understand how costly the revenue-generating process is.
- A high cost of revenue may indicate:
Poor cost control
Low operational efficiency - A low cost of revenue combined with high revenue indicates high profitability and business competitiveness.
Annual Cost of Revenue Zimmer Biomet Holdings
| 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2.19 B | 2.08 B | 2.02 B | 1.96 B | 1.82 B | 1.94 B | 2.27 B | 2.13 B | 2.38 B | - | - | - | - | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 2.38 B | 1.82 B | 2.09 B |
Quarterly Cost of Revenue Zimmer Biomet Holdings
| 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 559 M | 592 M | 550 M | 539 M | 554 M | 512 M | 519 M | 526 M | 501 M | - | 488 M | 511 M | 500 M | - | 491 M | 582 M | 436 M | - | 569 M | 424 M | 487 M | - | 536 M | 581 M | 553 M | - | 529 M | 584 M | 576 M | - | 501 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 279 M |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 592 M | 279 M | 518 M |
Cost of Revenue of other stocks in the Medical devices industry
| Issuer | Cost of Revenue | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Helius Medical Technologies
HSDT
|
583 K | $ 2.22 | 2.55 % | $ 1.35 M |  USA |
 |
OrthoPediatrics Corp.
KIDS
|
63.7 M | $ 17.26 | 1.29 % | $ 405 M | USA |
 |
LivaNova PLC
LIVN
|
448 M | $ 66.29 | 15.11 % | $ 3.62 B |  Britain |
 |
Myomo
MYO
|
14 M | $ 0.84 | -4.25 % | $ 35.2 M | USA |
 |
Allied Healthcare Products
AHPI
|
24.5 M | - | 3.58 % | $ 2.21 M | USA |
 |
Orthofix Medical
OFIX
|
256 M | $ 12.33 | -0.88 % | $ 488 M |  Curacao |
 |
Apollo Endosurgery
APEN
|
34.4 M | - | - | $ 475 M | USA |
 |
Alphatec Holdings
ATEC
|
232 M | $ 7.12 | -30.45 % | $ 1.07 B | USA |
 |
EDAP TMS S.A.
EDAP
|
37.6 M | $ 3.56 | 3.04 % | $ 133 M |  France |
 |
Aziyo Biologics
AZYO
|
5.7 M | - | 1.37 % | $ 20.5 M | USA |
 |
Insulet Corporation
PODD
|
768 M | $ 150.99 | -9.88 % | $ 10.6 B | USA |
 |
Avinger
AVGR
|
5.65 M | - | -20.74 % | $ 369 K | USA |
 |
Axonics Modulation Technologies
AXNX
|
76 M | - | - | $ 3.31 B | USA |
 |
BioSig Technologies
BSGM
|
57 K | - | 37.08 % | $ 85.7 M | USA |
 |
BIOLASE
BIOL
|
32.4 M | - | -13.19 % | $ 166 K | USA |
 |
Sintx Technologies
SINT
|
557 K | $ 2.47 | 1.86 % | $ 6.85 M | USA |
 |
Conformis
CFMS
|
38.8 M | - | - | $ 16.4 M | USA |
 |
Stryker Corporation
SYK
|
9.05 B | $ 291.1 | -1.42 % | $ 111 B | USA |
 |
ClearPoint Neuro
CLPT
|
14.3 M | $ 11.61 | 4.59 % | $ 329 M | USA |
 |
Cardiovascular Systems
CSII
|
63.4 M | - | 0.15 % | $ 844 M | USA |
 |
TransMedics Group
TMDX
|
243 M | $ 71.46 | -24.72 % | $ 2.43 B | USA |
 |
Tandem Diabetes Care
TNDM
|
469 M | $ 18.18 | -6.39 % | $ 1.24 B | USA |
 |
Cytosorbents Corporation
CTSO
|
10.6 M | $ 0.58 | -3.93 % | $ 36.1 M | USA |
 |
Delcath Systems
DCTH
|
11.8 M | $ 11.38 | -1.34 % | $ 408 M | USA |
 |
Neovasc
NVCN
|
556 K | - | - | $ 111 M |  Canada |
 |
IRIDEX Corporation
IRIX
|
33.4 M | $ 1.03 | -1.9 % | $ 17.4 M | USA |
 |
Dynatronics Corporation
DYNT
|
21.4 M | - | 14.99 % | $ 929 K | USA |
 |
Eargo
EAR
|
23 M | - | - | $ 10.2 M | USA |
 |
Varex Imaging Corporation
VREX
|
554 M | $ 11.95 | 3.6 % | $ 495 M | USA |
 |
Electromed
ELMD
|
14 M | $ 26.01 | 0.76 % | $ 220 M | USA |
 |
Vivos Therapeutics
VVOS
|
6.9 M | $ 0.71 | 0.65 % | $ 7.29 M | USA |
 |
Butterfly Network
BFLY
|
33.2 M | $ 4.66 | -3.32 % | $ 986 M | USA |
 |
Second Sight Medical Products
EYES
|
11.4 M | - | -0.97 % | $ 54.4 M | USA |
 |
GBS
GBS
|
1.81 M | - | -0.57 % | $ 7.12 M | USA |
 |
Globus Medical
GMED
|
958 M | $ 89.64 | -0.43 % | $ 12.1 B | USA |
 |
CONMED Corporation
CNMD
|
624 M | $ 36.89 | 0.68 % | $ 1.14 B | USA |
 |
Inspire Medical Systems
INSP
|
133 M | $ 46.24 | -4.17 % | $ 1.36 B | USA |
 |
Integer Holdings Corporation
ITGR
|
1.35 B | $ 86.32 | 0.55 % | $ 3 B | USA |
 |
Invacare Corporation
IVC
|
566 M | - | - | $ 24.7 M | USA |
 |
Edwards Lifesciences Corporation
EW
|
1.33 B | $ 82.62 | -0.35 % | $ 48.3 B | USA |